Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity - Additional Information (Details)

Shareholders' Equity - Additional Information (Details)												1 Months Ended	3 Months Ended		38 Months Ended
Shareholders' Equity - Additional Information (Details)	Oct. 17, 2022 USD ($)	Oct. 07, 2022 USD ($) $ / shares	Feb. 12, 2021 $ / shares shares	Feb. 10, 2021 $ / shares shares	Feb. 08, 2021 $ / shares shares	Oct. 31, 2020 $ / shares shares	Oct. 27, 2020 $ / shares shares	Jul. 02, 2020 $ / shares shares	Jun. 05, 2020 $ / shares shares	Jun. 03, 2020 $ / shares shares	Apr. 27, 2018 $ / shares shares	Jun. 30, 2020 $ / shares shares	Mar. 31, 2024 USD ($) Vote $ / shares shares	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares	May 03, 2023 $ / shares shares
Class Of Stock [Line Items]
Increase to authorized ordinary shares																	60,000,000
Ordinary shares, par value \| $ / shares													$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Ordinary shares, shares authorized													80,000,000		80,000,000	80,000,000
Number of vote per common share \| Vote													1
Common stock shares with preemptive rights													60,000,000		60,000,000
Number of ordinary shares not have preemptive or other subscription rights													20,000,000		20,000,000
Common stock rights and preferences													The holders of ordinary shares currently have preemptive rights over 60,000,000 ordinary shares and no preemptive or other subscription rights over 20,000,000 ordinary shares. There are no redemption or sinking fund provisions with respect to the authorized ordinary shares.
Authorized amount for sale of stock \| $	$ 100,000,000
Ordinary shares, shares issued													16,470,414		16,470,414	13,499,003
Proceeds from registered direct offerings, net of transaction costs \| $													$ 7,217,000	$ 235,000
Aggregate principal amount of exchangeable notes \| $															$ 40,691,000
Undesignated preferred shares, par value \| $ / shares													$ 0.01		$ 0.01	$ 0.01
Undesignated preferred shares, authorized													100,000,000		100,000,000	100,000,000
Undesignated preferred shares issued													0		0	0
Sales Agreement With H.C. Wainwright
Class Of Stock [Line Items]
Ordinary shares, par value \| $ / shares		$ 0.01
Maximum \| Sales Agreement With H.C. Wainwright
Class Of Stock [Line Items]
May offer and sell ordinary shares for aggregate gross sales proceeds \| $		$ 16,000,000
Private Placement \| Securities Purchase Agreement
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares									13,868
Warrants to purchase ordinary shares, exercise price \| $ / shares									$ 31.5465	$ 24.3
Warrants expiry date									Jun. 03, 2025	Dec. 05, 2025
Warrants exercisable date									Jun. 03, 2020
Percentage of ordinary shares issued to purchase warrants									7.00%
Private Placement \| Securities Purchase Agreement \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares										99,057
Private Placement \| June 30 SPA
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares								15,739
Warrants to purchase ordinary shares, exercise price \| $ / shares								$ 27.7965				$ 21.3
Warrants expiry date								Jun. 30, 2025				Jan. 02, 2026
Percentage of ordinary shares issued to purchase warrants								7.00%
Proceeds from exercise of warrants related to registered direct offering \| $													$ 1,796,000
Warrants exercised													84,317		84,317
Private Placement \| June 30 SPA \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares												112,422
October Offering
Class Of Stock [Line Items]
Proceeds from registered direct offerings, net of transaction costs \| $													$ 13,885,000
Number of warrants to purchase ordinary shares						125,641
Number of warrants exercised for ordinary shares													1,392,701		1,392,701
Warrants to purchase ordinary shares, exercise price \| $ / shares						$ 12.1875	$ 9.75
Warrants expiry date						Oct. 22, 2025	Oct. 27, 2025
Percentage of ordinary shares issued to purchase warrants						7.00%
October Offering \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares							1,346,153
February Underwritten Offering
Class Of Stock [Line Items]
Offering closing date				Feb. 10, 2021	Feb. 08, 2021
Additional ordinary shares that can be purchased by underwriter				347,826
Number of warrants to purchase ordinary shares													25,333		25,333
Warrants to purchase ordinary shares, exercise price \| $ / shares				$ 21.5625	$ 21.5625
Warrants expiry date				Feb. 03, 2026	Feb. 03, 2026
Percentage of ordinary shares issued to purchase warrants				7.00%	7.00%
Proceeds from warrants connected to registered direct offerings \| $													$ 546,000
February Underwritten Offering \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares				24,347	162,318
At-the-market agreement
Class Of Stock [Line Items]
Number of ordinary shares sold													2,971,411
Offering price per share \| $ / shares													$ 2.51		$ 2.51
Proceeds from registered direct offerings, net of transaction costs \| $													$ 7,200,000
February Registered Direct Offering
Class Of Stock [Line Items]
Offering closing date			Feb. 12, 2021
Number of warrants to purchase ordinary shares			81,666
Warrants to purchase ordinary shares, exercise price \| $ / shares			$ 37.5
Warrants expiry date			Feb. 09, 2026
Percentage of ordinary shares issued to purchase warrants			7.00%
Warrants to Purchase 19,890 Ordinary Shares \| Silicon Valley Bank and Life Sciences Fund II LLC
Class Of Stock [Line Items]
Warrants expiry date											Apr. 27, 2028
Series B Convertible Preferred Shares \| Silicon Valley Bank and Life Sciences Fund II LLC
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares											19,890
Warrants to purchase ordinary shares, exercise price \| $ / shares											$ 282.75
Undesignated Preferred Shares
Class Of Stock [Line Items]
Undesignated preferred shares, par value \| $ / shares													$ 0.01		$ 0.01
Undesignated preferred shares, authorized													100,000,000		100,000,000
Designated Preferred Shares
Class Of Stock [Line Items]
Undesignated preferred shares issued													0		0	0
Ordinary Shares \| Silicon Valley Bank and Life Sciences Fund II LLC
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares											1,326
Exchangeable Notes
Class Of Stock [Line Items]
Ordinary shares, shares issued													3,760,155		3,760,155
Aggregate principal amount of exchangeable notes \| $															$ 40,691,000
Aggregate principal amount \| $													$ 11,117,000		11,117,000
Exchangeable Notes \| Private Placement
Class Of Stock [Line Items]
Aggregate principal amount of exchangeable notes \| $															$ 40,691,000